Pioneering Science to Transform Patient Outcomes Half-Year Financial Report 2025 scroll for more Financial Highlights Group Net Revenues € 140.3 million Read More Cash Position € 3,091.5 million Read More Deferred Income € 954.1 million Read More R&D Expenses € 290.5 million Read More
